A 58-year-old man with chronic stable angina is on long-acting nitrates and a beta-blocker. He develops tolerance to nitrates and experiences frequent anginal episodes despite compliance. Regarding nitrate tolerance and antianginal drug properties, all of the following are correct EXCEPT:

Explanation

## Nitrate Tolerance and Antianginal Management ### Mechanism of Nitrate Tolerance (Option 1 — CORRECT) **Key Point:** Nitrate tolerance develops via **sulfhydryl depletion**. Nitrates require enzymatic bioconversion by mitochondrial aldehyde dehydrogenase (mtADH) to release NO. This process consumes sulfhydryl donors (cysteine, glutathione, dihydrolipoic acid). Depletion of these cofactors impairs NO generation. **Clinical Pearl:** This is why co-administration of **sulfhydryl donors** (ACE inhibitors, hydralazine, N-acetylcysteine) can restore nitrate efficacy. ### Nitrate-Free Interval (Option 2 — CORRECT) **High-Yield:** A **10–14 hour nitrate-free interval** daily is essential for preventing tolerance. This allows: - Replenishment of sulfhydryl cofactors - Restoration of mtADH activity - Recovery of NO-generating capacity **Mnemonic:** **NFI = No Tolerance Interval** — nitrate-free interval prevents nitrate tolerance. ### Ranolazine (Option 3 — CORRECT) **Key Point:** Ranolazine is a **late sodium current inhibitor** that indirectly reduces intracellular calcium overload by: 1. Inhibiting the late phase of the L-type calcium current (not the early phase) 2. Reducing Na⁺ influx → ↓ Na⁺/Ca²⁺ exchanger activity → ↓ intracellular Ca²⁺ 3. Reducing myocardial stiffness and improving diastolic function **Clinical Pearl:** Ranolazine does NOT lower heart rate or blood pressure, making it useful in patients with contraindications to beta-blockers or CCBs. ### Continuous Nitrate Use (Option 4 — INCORRECT) **Warning:** This is the FALSE statement. Continuous, uninterrupted use of long-acting nitrates **accelerates tolerance development**. The standard practice is: - Use long-acting nitrates WITH a daily nitrate-free interval (10–14 hours) - NOT continuous dosing without interruption **Clinical Pearl:** Patients on long-acting nitrates should be counseled to take their dose in the morning and skip the evening dose (or vice versa) to maintain a nitrate-free window. ## Nitrate Tolerance Prevention Strategy ```mermaid flowchart TD A[Patient on long-acting nitrates]:::outcome --> B{Continuous dosing?}:::decision B -->|Yes| C[Tolerance develops]:::urgent B -->|No - with NFI| D[Maintain sensitivity]:::action C --> E[Increase dose needed]:::urgent D --> F[Sustained antianginal effect]:::outcome E --> G[Diminishing returns]:::urgent F --> H[Optimal efficacy]:::outcome ``` ## Summary: Antianginal Strategies in Tolerance | Intervention | Mechanism | Efficacy | | --- | --- | --- | | Nitrate-free interval (10–14 h) | Sulfhydryl repletion | ✓✓ Prevents tolerance | | Sulfhydryl donors (ACE-I, NAC) | Restore cofactors | ✓ Restores efficacy | | Ranolazine addition | ↓ Late Na⁺ current | ✓ Improves symptoms | | Continuous nitrates | None | ✗ Accelerates tolerance | [cite:KD Tripathi 8e Ch 31; Harrison 21e Ch 297]